Robert B. Henderson

Stevenage, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study.

Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study.

Journal: Annals of the rheumatic diseases
Published: February 16, 2024

A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol.

A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol.

Journal: Trials
Published: October 06, 2022

A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndrome.

A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndrome.

Journal: JCI insight
Published: June 24, 2022

Sonoporation of Human Renal Proximal Tubular Epithelial Cells In Vitro to Enhance the Liberation of Intracellular miRNA Biomarkers.

Sonoporation of Human Renal Proximal Tubular Epithelial Cells In Vitro to Enhance the Liberation of Intracellular miRNA Biomarkers.

Journal: Ultrasound in medicine & biology
Published: September 22, 2021

Identifying cell-enriched miRNAs in kidney injury and repair.

Identifying cell-enriched miRNAs in kidney injury and repair.

Journal: JCI insight
Published: May 19, 2020

The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis.

The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis.

Journal: Arthritis research & therapy
Published: October 22, 2019

Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.

Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.

Journal: BMJ open
Published: March 23, 2019

Belimumab in kidney transplantation - Authors' reply.

Belimumab in kidney transplantation - Authors' reply.

Journal: Lancet (London, England)
Published: September 22, 2018

Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.

Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.

Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: August 10, 2018

Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial.

Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial.

Journal: Lancet (London, England)
Published: February 05, 2018

A distinct plasmablast and naïve B-cell phenotype in primary immune thrombocytopenia.

A distinct plasmablast and naïve B-cell phenotype in primary immune thrombocytopenia.

Journal: Haematologica
Published: October 06, 2015
Showing 1-11 of 11

Last Updated: 09/26/2026